Get the Stockscreener App
37.64
2.91%
-1.14
Harmony Biosciences Holdings Inc stock is traded at $37.64, with a volume of 201.18K.
It is down -2.91% in the last 24 hours and up +7.02% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
See More
Previous Close:
$38.78
Open:
$38.68
24h Volume:
201.18K
Relative Volume:
0.34
Market Cap:
$2.21B
Revenue:
$681.88M
Net Income/Loss:
$122.63M
P/E Ratio:
17.84
EPS:
2.11
Net Cash Flow:
$220.18M
1W Performance:
-2.89%
1M Performance:
+7.02%
6M Performance:
+12.22%
1Y Performance:
+18.06%
1-Day Range:
$37.40
$38.86
1-Week Range:
$37.40
$40.00
52-Week Range:
$28.14
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
37.68 | 2.21B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.88 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.49 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.66 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
(HRMY) Proactive Strategies - Stock Traders Daily
Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider? - StockNews.com
BlackRock, Inc.'s Strategic Acquisition in Harmony Biosciences H - GuruFocus.com
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? - Yahoo Finance
Top 5 US Stocks To Buy In February 2025 - Investing.com
SG Americas Securities LLC Grows Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
HRMY vs. RGEN: Which Stock Is the Better Value Option? - MSN
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia Sells 1,775 Shares - MarketBeat
Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells 1,629 Shares of Stock - MarketBeat
Jeffrey Dierks Sells 13,125 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock - MarketBeat
Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences (HRMY): Here's What You Should Know - Yahoo Finance
Vanguard Group Inc. Expands Stake in Harmony Biosciences Holdings Inc. - GuruFocus.com
Harmony Biosciences Stock Scores 80-Plus RS Rating - Yahoo! Voices
Harmony Biosciences' chief commercial officer sells $551,575 in stock - MSN
H.C. Wainwright maintains $75 target on Harmony Biosciences stock - MSN
Harmony Biosciences' chief commercial officer sells $551,575 in stock By Investing.com - Investing.com Australia
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
H.C. Wainwright maintains $75 target on Harmony Biosciences stock By Investing.com - Investing.com Australia
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Position Boosted by Pacer Advisors Inc. - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com
Why Harmony Biosciences Shares Are Gaining Attention - TipRanks
Learn to Evaluate (HRMY) using the Charts - Stock Traders Daily
Is Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Recent Stock Performance Tethered To Its Strong Fundamentals? - Yahoo Finance
Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CEO Sells 19,293 Shares of Stock - MarketBeat
Sandip Kapadia Sells 25,000 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Trading Down 4.5%Here's What Happened - MarketBeat
Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech (NASDAQ:HRMY) - Seeking Alpha
Harmony Biosciences CFO Sandip Kapadia sells $1m in stock By Investing.com - Investing.com Australia
Zacks.com featured highlights include Harmony Biosciences, Ingevity, Gulfport Energy and Pitney Bowes - Yahoo Finance
Harmony Biosciences CFO Sandip Kapadia sells $1m in stock - MSN
Cantor Fitzgerald Forecasts HRMY FY2025 Earnings - Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 1,123 Shares - MarketBeat
Harmony Biosciences Reports Strong Revenue Growth and Outlines Ambitious 2025 Strategy - MSN
HRMY: 3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare - StockNews.com
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Equities Analysts Offer Predictions for HRMY FY2025 Earnings - MarketBeat
Analysts Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) PT at $55.00 - MarketBeat
Harmony Biosciences chief commercial officer sells shares worth $1.15m By Investing.com - Investing.com Canada
ARS Investment Partners LLC Invests $841,000 in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - MarketBeat
Should Value Investors Buy Harmony Biosciences (HRMY) Stock? - Yahoo Finance
Harmony Biosciences stock reaffirms buy rating ahead of Q4 results - MSN
What is HC Wainwright's Forecast for HRMY FY2029 Earnings? - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 10,507 Shares - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Harmony Biosciences (NASDAQ:HRMY) - MarketBeat
Harmony Biosciences stock reaffirms buy rating ahead of Q4 results By Investing.com - Investing.com Australia
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harmony Biosciences Holdings Inc Stock (HRMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dierks Jeffrey | CHIEF COMMERCIAL OFFICER |
Jan 24 '25 |
Option Exercise |
25.47 |
15,812 |
402,806 |
13,125 |
| Dierks Jeffrey | CHIEF COMMERCIAL OFFICER |
Jan 24 '25 |
Sale |
37.31 |
13,125 |
489,634 |
0 |
| Dierks Jeffrey | CHIEF COMMERCIAL OFFICER |
Jan 27 '25 |
Sale |
38.02 |
1,629 |
61,941 |
0 |
| Dayno Jeffrey M. | PRESIDENT, CEO |
Jan 24 '25 |
Option Exercise |
0.00 |
10,500 |
0 |
10,500 |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER |
Jan 24 '25 |
Option Exercise |
0.00 |
3,812 |
0 |
3,812 |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER |
Jan 27 '25 |
Sale |
38.05 |
1,775 |
67,547 |
0 |
| Serafin Andrew | CHIEF STRATEGY OFFICER |
Jan 24 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
2,500 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):